Wild-type IDH1 inhibition enhances chemotherapy response in melanoma

BACKGROUND: Alternative treatment strategies in melanoma beyond immunotherapy and mutation-targeted therapy are urgently needed. Wild-type isocitrate dehydrogenase 1 (wtIDH1) has recently been implicated as a metabolic dependency in cancer. The enzyme protects cancer cells under metabolic stress, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zarei, Mehrdad, Hajihassani, Omid, Hue, Jonathan J., Graor, Hallie J., Loftus, Alexander W., Rathore, Moeez, Vaziri-Gohar, Ali, Asara, John M., Winter, Jordan M., Rothermel, Luke D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509573/
https://www.ncbi.nlm.nih.gov/pubmed/36153582
http://dx.doi.org/10.1186/s13046-022-02489-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509573/
https://www.ncbi.nlm.nih.gov/pubmed/36153582
http://dx.doi.org/10.1186/s13046-022-02489-w

Ejemplares similares